Healthcare · Biotechnology
Price
$11.44
Market Cap
$297.5M
Employees
30
Beta
0.95
Avg Volume
1,783,167
CEO
Carl Spana
Business Description
Palatin Technologies, Inc. is a biopharmaceutical firm specializing in the creation of precise, receptor-targeting treatments for various medical conditions throughout the United States. Its flagship product is Vyleesi, a melanocortin receptor (MCr) agonist prescribed for premenopausal women experiencing hypoactive sexual desire disorder. The company's pipeline also includes oral PL8177, a selective MC1r agonist peptide that has successfully concluded Phase I clinical trials for inflammatory bowel diseases. Additionally, Palatin is advancing PL9643, a peptide melanocortin agonist that engages multiple MCr, including MC1r and MC5r, intended for anti-inflammatory ocular conditions such as dry eye disease. It is also developing other melanocortin peptides to address diabetic retinopathy. In the cardiovascular realm, the firm is pursuing PL3994, an NPR-A agonist and synthetic analogue of the endogenous neuropeptide hormone atrial natriuretic peptide. A further compound, PL5028, acts as an NPR-A and NPR-binder, designed to tackle cardiovascular and fibrotic disorders, notably by mitigating cardiac hypertrophy and fibrosis. Established in 1986, the company maintains its principal operations in Cranbury, New Jersey.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.36
Stock Price: $11.44
EPS (Diluted): -32.15
EPS (Diluted): -32.15
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
-0.79
Stock Price: $11.44
Total Equity: -$4.78M
Shares: 538,348
Total Equity: -$4.78M
Shares: 538,348
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.08
Market Cap: $297.51M
Total Debt: $0.00
Cash: $2.56M
EBITDA: -$17.03M
Total Debt: $0.00
Cash: $2.56M
EBITDA: -$17.03M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$1.4M
Market Cap: $297.51M
Total Debt: $0.00
Cash: $2.56M
Total Debt: $0.00
Cash: $2.56M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $11.44
Revenue: $0.00
Shares: 538,348
Revenue: $0.00
Shares: 538,348
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: $0.00
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$17.46M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$17.31M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
CALCNet Income / Total Equity
362.3%
Net Income: -$17.31M
Total Equity: -$4.78M
Total Equity: -$4.78M
ROIC (Profit from all invested capital)
CALCNOPAT / Invested Capital
237.8%
Operating Income: -$17.46M
Tax Rate: 0.0%
Equity: -$4.78M
Total Debt: $0.00
Cash: $2.56M
Tax Rate: 0.0%
Equity: -$4.78M
Total Debt: $0.00
Cash: $2.56M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.36
Current Assets: $2.92M
Current Liabilities: $8.01M
Current Liabilities: $8.01M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: -$4.78M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: -$4.78M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 538,348
Shares: 538,348
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$-8.87
Total Equity: -$4.78M
Shares: 538,348
Shares: 538,348
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-39.58
Operating CF: -$21.31M
CapEx: -$3.00
Shares: 538,348
CapEx: -$3.00
Shares: 538,348
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $11.44
Stock Price: $11.44
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$17.31M
Net Income: -$17.31M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares PTN against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 22, 2026 12:06am (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $-188,597 | $1.5M | $4.9M | $4.5M | $0 |
| Cost of Revenue | $147,840 | $217,529 | $418,470 | $97,637 | $0 |
| Gross Profit | $-336,437 | $1.3M | $4.4M | $4.4M | $0 |
| Operating Expenses | $33.0M | $37.8M | $36.9M | $26.9M | $17.5M |
| Operating Income | -$33.4M | -$36.6M | -$32.5M | -$22.5M | -$17.5M |
| Net Income | -$33.6M | -$36.2M | -$24.0M | -$29.7M | -$17.3M |
| EBITDA | -$33.5M | -$35.7M | -$28.4M | -$29.4M | -$17.0M |
| EPS | $-3.55 | $-3.79 | $-2.21 | $-2.02 | $-32.15 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 22, 2026 12:06am (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $60.1M | $29.9M | $8.0M | $9.5M | $2.6M |
| Total Current Assets | $65.9M | $34.6M | $16.3M | $9.8M | $2.9M |
| Total Assets | $67.3M | $36.1M | $17.9M | $10.7M | $3.3M |
| Current Liabilities | $10.5M | $16.3M | $15.1M | $9.7M | $8.0M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $17.6M | $19.8M | $19.9M | $10.9M | $8.0M |
| Total Equity | $49.7M | $16.3M | -$2.0M | $-111,497 | -$4.8M |
| Retained Earnings | -$351.8M | -$388.0M | -$412.0M | -$441.8M | -$459.1M |
Cash Flow (Annual)
Last updated: Jun 22, 2026 12:06am (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$22.6M | -$29.9M | -$28.4M | -$31.5M | -$21.3M |
| Capital Expenditure | $-5,722 | $-261,374 | $-433,927 | $-42,526 | $-3 |
| Free Cash Flow | -$22.7M | -$30.2M | -$28.9M | -$31.5M | -$21.3M |
| Acquisitions (net) | $0 | $0 | $0 | $9.5M | $3.1M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $-93,638 | $-221,311 | $0 | $0 | $0 |
| Net Change in Cash | -$22.7M | -$30.2M | -$21.9M | $1.5M | -$7.0M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 12:50am (9h ago)| Metric | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Revenue |
$5.3M $5.3M – $5.3M
|
$74.5M $74.5M – $74.5M
|
$152.4M $152.4M – $152.4M
|
$111.3M $111.3M – $111.3M
|
| EBITDA |
-$1.0M -$1.0M – -$1.0M
|
-$14.9M -$14.9M – -$14.9M
|
-$30.5M -$30.5M – -$30.5M
|
-$22.3M -$22.3M – -$22.3M
|
| Net Income |
$-532,965 $-532,965 – $-532,965
|
$1.0M $1.0M – $1.0M
|
$3.0M $3.0M – $3.0M
|
$279,941 $279,941 – $279,941
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 22, 2026 12:06am (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +878.6% | +230.5% | -7.5% | -100.0% |
| Gross Profit Growth | +471.8% | +254.6% | -1.0% | -100.0% |
| Operating Income Growth | -9.6% | +11.3% | +30.7% | +22.4% |
| Net Income Growth | -7.8% | +33.6% | -23.7% | +41.8% |
| EBITDA Growth | -6.4% | +20.4% | -3.4% | +42.0% |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for PTN — it's generated by the pipeline (
market-narrative step).
No community reviews yet for PTN.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30